Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data

BACKGROUND Friedreich's ataxia is a rare autosomal recessive neurodegenerative disorder. Here we report cross-sectional baseline data to establish the biological and clinical characteristics for a prospective, international, European Friedreich's ataxia database registry. METHODS Within the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) framework, we assessed a cohort of patients with genetically confirmed Friedreich's ataxia. The primary outcome measure was the Scale for the Assessment and Rating of Ataxia (SARA) and secondary outcome measures were the Inventory of Non-Ataxia Signs (INAS), the performance-based coordination test Spinocerebellar Ataxia Functional Index (SCAFI), the neurocognitive phonemic verbal fluency test, and two quality-of-life measures: the activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale and EQ-5D. The Friedreich's ataxia cohort was subdivided into three groups: early disease onset (≤14 years), intermediate onset (15-24 years), and late onset (≥25 years), which were compared for clinical characteristics and outcome measures. We used linear regression analysis to estimate the annual decline of clinical outcome measures based on disease duration. This study is registered with ClinicalTrials.gov, number NCT02069509. FINDINGS We enrolled 592 patients with genetically confirmed Friedreich's ataxia between Sept 15, 2010, and April 30, 2013, at 11 sites in seven European countries. Age of disease onset was inversely correlated with the number of GAA repeats in the frataxin (FXN) gene: every 100 GAA repeats on the smaller repeat allele was associated with a 2·3 year (SE 0·2) earlier onset. Regression analyses showed significant estimated annual worsening of SARA (regression coefficient 0·86 points [SE 0·05], INAS (0·14 points [0·01]), SCAFI Z scores (-0·09 [0·01]), verbal fluency (-0·34 words [0·07]), and ADL (0·64 points [0·04]) during the first 25 years of disease; the regression slope for health-related quality-of-life state from EQ-5D was not significant (-0·33 points [0·18]). For SARA, the predicted annual rate of worsening was significantly higher in early-onset patients (n=354; 1·04 points [0·13]) and intermediate-onset patients (n=137; 1·17 points [0·22]) than in late-onset patients (n=100; 0·56 points [0·10]). INTERPRETATION The results of this cross-sectional baseline analysis of the EFACTS cohort suggest that earlier disease onset is associated with larger numbers of GAA repeats and more rapid disease progression. The differential estimated progression of ataxia symptoms related to age of onset have implications for the design of clinical trials in Friedreich's ataxia, for which SARA might be the most suitable measure to monitor disease progression. FUNDING European Commission.

[1]  B. Ravina,et al.  Predictors of progression in patients with Friedreich ataxia , 2008, Movement disorders : official journal of the Movement Disorder Society.

[2]  Jacob Cohen Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[3]  D. Geschwind,et al.  Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. , 2005, Archives of neurology.

[4]  M. Pandolfo Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations. , 2006, Methods in molecular medicine.

[5]  J. Schulz,et al.  Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales , 2013, Journal of neurochemistry.

[6]  J. Schulz,et al.  Diagnosis and treatment of Friedreich ataxia: a European perspective , 2009, Nature Reviews Neurology.

[7]  T Klockgether,et al.  The natural history of degenerative ataxia: a retrospective study in 466 patients. , 1998, Brain : a journal of neurology.

[8]  C. Angelini,et al.  Exploring mental status in Friedreich's ataxia: a combined neuropsychological, behavioral and neuroimaging study , 2006, European journal of neurology.

[9]  A. Dürr,et al.  Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. , 2013, Brain : a journal of neurology.

[10]  R. Hewer Study of Fatal Cases of Friedreich's Ataxia , 1968, British medical journal.

[11]  N. Drouot,et al.  Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. , 2009, Brain : a journal of neurology.

[12]  R. Hewer,et al.  Diabetes mellitus in Friedreich's ataxia. , 1968, Journal of neurology, neurosurgery, and psychiatry.

[13]  Dagmar Timmann,et al.  Comparison of three clinical rating scales in Friedreich ataxia (FRDA) , 2009, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Baliko,et al.  Scale for the assessment and rating of ataxia , 2006, Neurology.

[15]  T. Ashizawa,et al.  Health related quality of life measures in Friedreich Ataxia , 2008, Journal of the Neurological Sciences.

[16]  D. Timmann,et al.  SCA Functional Index , 2008, Neurology.

[17]  A Dürr,et al.  Clinical and genetic abnormalities in patients with Friedreich's ataxia. , 1996, The New England journal of medicine.

[18]  K. Bushara,et al.  Friedreich Ataxia Clinical Outcome Measures , 2012, Journal of child neurology.

[19]  M. Küper,et al.  Inventory of Non-Ataxia Signs (INAS): Validation of a New Clinical Assessment Instrument , 2012, The Cerebellum.

[20]  Eva Petkova,et al.  SYMPOSIUM ON APPLIED REGRESSION Statistical Methods for Comparing Regression Coefficients between Models1 , 1995 .

[21]  P. Patel,et al.  Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion , 1996, Science.

[22]  P Trouillas,et al.  Friedreich's ataxia: Point mutations and clinical presentation of compound heterozygotes , 1999, Annals of neurology.

[23]  P. Friedreich,et al.  Ueber degenerative Atrophie der spinalen Hinterstränge , 2005, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[24]  Alex R. Piquero,et al.  Testing for the Equality of Maximum-Likelihood Regression Coefficients Between Two Independent Equations , 1998 .

[25]  M. Hallett,et al.  Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale , 2005, Neurology.

[26]  K. Bushara,et al.  Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design , 2010, Movement disorders : official journal of the Movement Disorder Society.

[27]  R. Baloh,et al.  Late-onset pure cerebellar ataxia: Differentiating those with and without identifiable mutations , 2005, Journal of the Neurological Sciences.

[28]  S. Rivaud-Pechoux,et al.  Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. , 2007, Archives of neurology.

[29]  A. Harding Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. , 1981, Brain : a journal of neurology.